A network meta-analysis for efficacies and toxicities of different concurrent chemoradiotherapy regimens in the treatment of locally advanced non-small cell lung cancer

Table 6 Inconsistency tests for efficacies of different CCRT regimens in the treatment of LA-NSCLC

Pairwise comparisons	Direct OR values				Indirect OR values				P values
Pairwise comparisons	ORR	1-yera OS rate	2-year OS rate	3-year OS rate	ORR	1-yera OS rate	2-year OS rate	3-year OS rate	ORR	1-yera OS rate	2-year OS rate	3-year OS rate
A VS. B	0.91	0.13	-0.24	-1.25	-0.59	0.36	-0.74	-1.64	0.122	0.772	0.449	0.651
A VS. D	0.13	-0.05	0.01	0.12	-0.15	1.59	1.75	2.10	0.990	0.949	0.948	0.945
A VS. E	1.48	-0.69	-1.20	-1.13	1.49	-0.92	-0.70	-0.74	0.122	0.772	0.449	0.651
B VS. G	0.14	-0.25	0.03	0.41	-0.26	-0.21	-0.08	0.35	0.581	0.916	0.775	0.879
B VS. N	-0.29	-0.30	-0.28	-0.11	-0.53	-0.27	-0.34	-0.15	0.764	0.954	0.882	0.941
C VS. D	1.93	NR	NR	NR	-0.23	NR	NR	NR	0.981	NR	NR	NR
D VS. H	0.36	-0.49	0.10	-0.56	-0.19	1.23	1.94	1.57	0.982	0.948	0.946	0.943
E VS. G	-0.45	0.81	0.49	-0.09	1.04	0.57	0.99	0.29	0.122	0.772	0.449	0.651
F VS. H	-0.49	-0.16	-0.12	-0.09	0.05	-2.00	-2.13	-2.41	0.983	0.947	0.944	0.941
F VS. I	-0.37	-0.47	-1.16	-1.12	-0.87	1.60	1.22	1.61	0.985	0.944	0.939	0.936
G VS. N	-0.43	-0.04	-0.31	-0.53	-0.19	-0.07	-0.25	-0.50	0.764	0.954	0.882	0.941
I VS. K	-0.20	-1.41	-1.75	-1.59	-0.65	0.83	0.91	1.47	0.988	0.943	0.935	0.934
K VS. L	0.79	0.03	0.89	0.72	-0.05	4.53	6.26	6.85	0.997	0.982	0.979	0.976
K VS. O	0.15	1.25	0.91	NR	-0.68	5.75	6.28	NR	0.997	0.982	0.979	NR
K VS. P	0.97	0.94	0.82	0.64	0.13	5.44	6.19	6.76	0.997	0.982	0.979	0.976
K VS. Q	0.76	NR	NR	NR	-0.08	NR	NR	NR	0.997	NR	NR	NR
K VS. R	0.94	0.28	0.78	0.93	0.11	4.78	6.15	7.05	0.997	0.982	0.978	0.976

A, CCRT (cisplatin + etoposide); B, CCRT (carboplatin + paclitaxel); C, CCRT (pemetrexed + carboplatin); CCRT, concurrent chemoradiotherapy; D, CCRT (pemetrexed + cisplatin); E, CCRT (docetaxel + cisplatin); F, CCRT (S-1 + cisplatin); G, CCRT (mitomycin + vindesine + cisplatin); H, CCRT (cisplatin + vinorelbine); I, CCRT (cisplatin); K, RT; L, CCRT (5-FU); LA-NSCLC Locally advanced non-small cell lung cancer; N, CCRT (irinotecan + carboplatin); NR Not report; O, CCRT (nedaplatin); OR Odds radios; ORR Objective response rate, OS Overall survival; Q, CCRT (paclitaxel); R, CCRT (carboplatin)

ISSN: 1471-2407